Qiagen saw the highest growth of 2.66% in patent filings in April and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.66% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Qiagen’s patent filings and grants. Buy the databook here.
Qiagen has been focused on protecting inventions in European Patent Office(EPO) with five publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 25% filings and 100% grants. The European Patent Office(EPO), United States(US), World Intellectual Property Organization(WIPO), and Australia(AU) patent Office are among the top ten patent offices where Qiagen is filings its patents. Among the top granted patent authorities, Qiagen has 100% of its grants in European Patent Office(EPO).
Thermo Fisher Scientific and Roche could be the strongest competitors for Qiagen
In terms of grant share, Qiagen stands in ninth position among its competitors. Thermo Fisher Scientific and Roche secured the top positions according to recent patent publication data.
Patents related to genomics and industrial automation lead Qiagen's portfolio
Qiagen has the highest number of patents in genomics followed by, industrial automation. For genomics, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Laboratory equipment related patents lead Qiagen portfolio
Qiagen has highest number of patents in laboratory equipment.
For comprehensive analysis of Qiagen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.